Equities Analysts Set Expectations for Hikma Pharmaceuticals Plc’s FY2018 Earnings (OTCMKTS:HKMPF)

Share on StockTwits

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) – Stock analysts at Jefferies Financial Group issued their FY2018 EPS estimates for Hikma Pharmaceuticals in a research note issued on Monday, October 15th, according to Zacks Investment Research. Jefferies Financial Group analyst J. Vane-Tempest forecasts that the company will post earnings of $1.21 per share for the year. Jefferies Financial Group also issued estimates for Hikma Pharmaceuticals’ FY2019 earnings at $1.25 EPS, FY2020 earnings at $1.32 EPS, FY2021 earnings at $1.41 EPS and FY2022 earnings at $1.49 EPS.

Separately, Zacks Investment Research cut Hikma Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $27.00 target price for the company. in a report on Wednesday, October 17th.

Hikma Pharmaceuticals stock traded down $2.40 during trading hours on Wednesday, hitting $24.00. The stock had a trading volume of 201 shares, compared to its average volume of 138. The stock has a market cap of $6.03 billion, a price-to-earnings ratio of 22.86, a price-to-earnings-growth ratio of 2.93 and a beta of 0.07. Hikma Pharmaceuticals has a fifty-two week low of $12.00 and a fifty-two week high of $26.40.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Further Reading: What are no-load funds?

Get a free copy of the Zacks research report on Hikma Pharmaceuticals (HKMPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.